Standards & Regulation

MSD describes drug price negotiation program as “sham” and “tantamount to extortion”

Misbranded drugs, unapproved drugs, and companies who don’t know that ophthalmic drugs should be manufactured in a sterile environment…

Child exposure to pharmaceutical substances appears to be decreasing, but what more can packaging companies do to push the trend?

A new class of modern cloud systems promises the next step change in QC productivity and data integrity.

The first Humira biosimilar in the US is here, but market penetration could be a challenge.

New technologies offer cheaper modes of manufacture – here’s how and why the world’s less wealthy countries could seize the moment.

Anti-vaccine activists are suing a number of prominent media outlets, including Reuters, the Washington Post, the BBC, and the Associated Press.

What can cell and gene do to avoid a seemingly inevitable rush on supporting products and services?

Why critical starting materials are crucial to the production of cell and gene therapies, and among them cord blood deserves particular attention

In the face of economic uncertainty in a post-pandemic world, how will the cell and gene field respond?